Epithalon
Ala-Glu-Asp-Gly Tetrapeptide (Epitalon)
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
there are at least 3 human research trials all in Russia, there is plenty of animal work. Even if its mechanism is not widely studied its molecule and the molecule's structure, chemical properties and more are well defined.
Counted on the record: 1 human study, 5 animal studies, 3 lab studies.
The stored record mixes Epitalon, Epithalamin, cell studies, animal studies, and human cohorts. No normalized total is assigned.
- FDA
- Not approved. Reviewed by the FDA Pharmacy Compounding Advisory Committee in July 2026 among seven nominated peptides, with FDA briefing documents proposing it not be added to the 503A bulk drug substances list (advisory input, not a final agency determination).
- WADA
- Not listed by name; captured by the S0 Non-Approved Substances category, so treated as prohibited in sport at all times.
Reference only. Not medical advice.
What can go wrong
Sold as a research chemical, not for human use, with no purity or sterility oversight; efficacy claims come from a single unreplicated research lineage, and activating telomerase carries a theoretical proliferation/cancer concern.
Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about Epithalon. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
A four-amino acid peptide derived from Epithalamin, a pineal gland extract. The most-studied compound in the Khavinson Soviet bioregulator system, 700+ papers, almost all from one Russian institution. Famous for telomerase activation in cell culture. No Western RCT exists.
Soviet Cold War science. Classified until 1991. Telomere claims no Western lab has verified.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Epithalon is a four-amino-acid peptide studied mainly in cells. Laboratory studies report longer telomeres through telomerase or an alternative telomere-maintenance pathway, and other experiments propose effects on chromatin and gene expression. These are cell findings: no human dosing study has shown that Epithalon activates telomerase, slows aging, or extends life in people.
- Step 1Telomerase Activation:stimulate human telomerase reverse transcriptase (hTERT) expression. This enzyme rebuilds and maintains telomeres,the protective caps at the ends of chromosomes,potentially delaying cellular senescence and death.
- Step 2Melatonin/ Circadian Regulationin preclinical and older animal/primate studies to restore or normalize melatonin secretion, which supports sleep quality and circadian alignment.
- Step 3Antioxidant/Gene Modulationmay decrease reactive oxygen species (ROS), reduce lipid peroxidation, influence protein synthesis, and alter immune-related markers like interleukin-2 mRNA levels.
Epithalon acts primarily by upregulating telomerase activity to lengthen telomeres and by stimulating pineal melatonin production to help regulate circadian rhythms
Synthetic tetrapeptide Ala-Glu-Asp-Gly, derived from pineal epithalamin.
- Type
- Tetrapeptide (AEDG)
- Origin
- Pineal extract (epithalamin)
- Signature
- Telomerase activation
- Also
- Melatonin / circadian
- Approved
- No
- FDA review
- July 2026
The Telomerase Double-Edge
In cultured human cells, research groups have reported telomerase activation, alternative telomere maintenance, and longer telomeres after Epithalon exposure. Laboratory work also proposes that the short peptide can interact with DNA-associated processes and alter gene expression. None of those experiments demonstrates the same pathway in a treated person. Telomere length is not itself a clinical outcome, and broadly increasing telomere maintenance has unresolved safety implications because cancer cells can use the same systems.
How it is taken
Research (sealed vial)
lyophilizate Epithalon in sealed lyophilizate samples. A patent monitored sealed lyophilizate vials for up to 365 days at 35 C and standard humidity. The patent test is not an approved-product label and does not establish home-storage or post-reconstitution stability. Patent accelerated-storage experiment.
Research
aqueous laboratory solution Epithalon at 1 mg/mL in demineralized water at about pH 5.6. A patent monitored the aqueous solution at 40 C and 55% humidity for up to 20 days. The test conditions do not establish a finished-vial shelf life, reconstitution period, or consumer storage instruction. Patent accelerated-storage experiment.
Injection
Recorded because this entry documents injectable use. The Atlas holds no vial, reconstitution or storage detail for it.
Safety in detail
- Epithalon activates telomerase, a system cancer cells also use, which leaves a real open question about cancer risk.
A topic inside this one
Epitalon, also spelled Epithalon, is a synthetic peptide (a short chain of amino acids, the building blocks of proteins) made of just four amino acids, with the sequence Ala-Glu-Asp-Gly, abbreviated AEDG. It was developed in Russia as a defined synthetic stand-in for Epithalamin, an extract of the pineal gland, a small gland in the brain that helps regulate sleep and daily rhythms (the body's roughly 24-hour internal clock, called the circadian rhythm) via the hormone melatonin. It is used and studied for a range of purposes: general anti-aging use, claimed longevity and telomere effects, and sleep and circadian or melatonin-related claims. The most repeated and most contested claim is that it switches on telomerase, an enzyme that rebuilds telomeres (the protective caps on the ends of chromosomes that shorten as cells age), and thereby slows aging; that telomerase and lifespan work comes mainly from laboratory cell studies, animal experiments, and Russian research groups, and has not been independently replicated in large Western trials. A crucial distinction sits at the center of the story: much of the older Russian human data, including the strongest mortality findings, used the crude pineal extract Epithalamin rather than the synthetic peptide that most people buy today. Epitalon is not approved as a medicine anywhere and in the US is sold as an unregulated research chemical. Claims that it reverses aging or extends human lifespan are not established by the kind of large, independent human trials regulators rely on.
PROMINENT RISK: Epitalon is not approved as a medicine in any country and reaches US buyers as an unregulated research chemical of uncertain purity, dose, and sterility. The signature telomerase and lifespan claims rest on cell-culture work, animal studies, and small Russian human studies, much of which used the crude pineal extract rather than the synthetic peptide and has not been independently replicated. Telomerase activation also raises theoretical cancer concerns, since cancer cells exploit telomerase. Long-term human safety is unknown. Injecting non-sterile product carries infection risk.
- Structure
- A chain of four amino acids (Ala-Glu-Asp-Gly), abbreviated AEDG
- Source idea
- Synthetic version of a pineal gland extract called Epithalamin
- Studied and promoted for
- Longevity and anti-aging, telomere effects, and sleep and circadian (melatonin-related) claims
- Central caveat
- The contested telomerase claim rests largely on cell and animal work, and the strongest human data used the crude extract, not the synthetic peptide
- Claimed longevity and anti-aging support
- Claimed telomere maintenance
- Sleep and circadian rhythm support
- Pineal gland and melatonin-related claims
The peptide originates with Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, whose lineage runs back through Soviet military medicine research of the 1970s led by Khavinson and Vyacheslav Morozov on organ derived peptide extracts. Epithalamin, the crude bovine pineal preparation, came first and was registered in Russia as a bioregulator. AEDG, the four residue synthetic version, was designed later as a defined chemical stand in for that extract, and the two names are still used almost interchangeably in the literature, which is a persistent source of confusion when readers try to trace which studies tested which substance. The Latinised spelling Epithalon and the transliterated Epitalon both appear in Khavinson's own English language papers. In the West the compound entered circulation through research chemical vendors in the mid 2000s and was amplified by longevity forums, biohacker podcasts, and later by Reddit peptide communities, where it is commonly named in stacks alongside thymalin, thymogen, and GHK Cu, all of which trace to the same Russian bioregulator tradition. Those stack pairings are community conventions rather than protocols from any laboratory.
Epitalon traces to Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, work that grew out of Soviet-era research begun in the 1970s on Epithalamin, a peptide extract of the pineal gland. Khavinson's group synthesized the four-amino-acid peptide AEDG (Epitalon) as a defined version of that extract and, from the 1990s onward, published animal and human studies reporting reduced mortality and slowed aging. Notably, the long human follow-up data (including reports of roughly 1.6 to 2.5-fold lower mortality over 6 to 15 years) largely used Epithalamin, the crude pineal extract, rather than synthetic Epitalon. What is validated: Khavinson's role as originator and the existence of the Russian study program. What is not validated: the telomerase and lifespan-extension claims for the general public, which lack large independent non-Russian replication and have drawn methodological criticism.
- 1970sSoviet research begins on Epithalamin, a pineal gland peptide extract
- 1990sKhavinson's group synthesizes the AEDG tetrapeptide, Epitalon
- 2000sRussian studies report lifespan and mortality effects, mostly using the crude extract
- 2003Cell-culture reports of telomerase activation and telomere lengthening published
- 2010sEpitalon spreads through Western longevity and biohacker markets as a research chemical
- 24 Jul 2026FDA PCAC votes 7 to 4, with one abstention, to recommend Epitalon for the Section 503A bulks list. The advisory vote is not final rulemaking.
Often saidMyth: Epitalon is proven to extend human lifespan.
ActuallyReality: The strongest mortality data used the crude pineal extract Epithalamin, not the synthetic peptide most people buy, and lack large independent replication.
Often saidMyth: Activating telomerase is simply anti-aging.
ActuallyReality: Telomerase activation is biologically two-sided, since cancer cells also rely on it; human safety is unproven.
Children and teenagers
Epithalon is an anti-aging peptide with no pediatric indication, no pediatric data and no rationale for use in anyone under 18. The telomerase-activation mechanism makes it especially inappropriate for children, whose cells already divide vigorously and in whom an unresolved cancer concern weighs even heavier. Any use in a minor would be unstudied misuse with no benefit to justify the risk.
What people get wrong
Often saidIt is proven to extend human lifespan
ActuallyOne Russian observational cohort reported a mortality reduction. No randomized, blinded, independently replicated trial has confirmed it.
Often saidTelomerase activation is unambiguously good
ActuallyTelomerase is also how cancer cells achieve immortality. The same switch cuts both ways.
Who profits, and who pushes back
Reproducibility concern
The vast majority of research originates from one institution under one researcher. Science resting on a single group warrants caution regardless of how promising it looks.
Telomerase / cancer paradox
Activating telomerase in aging cells could theoretically support cancer cell survival through the identical pathway.
Independent gerontology researchers
The lifespan claims rest largely on small or animal studies and the original group's own work, not independent replication.
Dr. Eric Topol
No randomized controlled trials. The evidence is not there.
Oncology-aware clinicians
Boosting telomerase is biologically double-edged because cancer cells rely on it; human safety is unproven.
Drug regulators (FDA)
Epitalon is not approved anywhere and its benefit and safety have not been established in formal review.
Andrew Huberman
Covered in his comprehensive peptide episode. General wellness sponsors only.
Longevity supplement vendors
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Market Epitalon as a telomere and anti-aging peptide; profit from sales
Dave Asprey
Longevity-stacking discussions. General supplement business interests.
Anti-aging influencers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Frequently use affiliate codes alongside personal endorsement
Khavinson research group
Publish the supportive studies; hold scientific and reputational interest
Epithalon is sold both as a branded bioregulator within the Russian Cytogen and Cytomax lines and, more widely, as a gray-market research peptide, with longevity clinics building anti-aging protocols around it. There is no approved product, so the money flows to supplement makers, research vendors and clinics rather than to a proven medicine. Its unusually deep research base and famous telomerase story make it one of the most commercially prominent longevity peptides despite the absence of approval.
Where the research comes from
Most of the published research on this comes from one place. 95% of it is from Russia. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Russia | 95% |
| Other | 5% |
Research published from: Russia (>95%).
How we got here
Epithalon began as Epithalamin, a crude polypeptide extract from the bovine pineal gland developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology; the synthetic tetrapeptide Epithalon (Ala-Glu-Asp-Gly, or AEDG) was later designed as its defined active analogue. In Russia the pineal bioregulator is sold as the natural Cytomax capsule Endoluten (A-8), whereas in Western markets Epithalon (Epitalon) circulates mainly as an injectable research chemical rather than an approved product.
Epithalon began as epithalamin, an extract of the pineal gland studied in the Soviet Union for effects on aging. In the 1980s Vladimir Khavinson distilled it to the tetrapeptide AEDG and spent four decades studying it. A landmark 2003 paper reported telomerase activation and telomere elongation in human cells, animal studies showed lifespan extension and fewer tumors, and a long-term human cohort claimed reduced mortality, building an unusually deep, if methodologically limited, research base. In 2025 an independent Western lab confirmed the telomere mechanism in cell culture, and in 2026 the FDA removed it from the restricted compounding list and scheduled an advisory review, marking its first formal Western regulatory attention.
Soviet era
- 1970Epithalamin and later EpitalonVladimir Khavinson began the peptide bioregulation research program that produced the pineal extract Epithalamin and later the synthetic tetrapeptide Epitalon
2000s
From 2000
- June 2000Patent on the synthesis of EpitalonDescribing Epitalon properties, formulation, chemical structure.
- 2005From Epithalamin a Russian MedicineEpitalon described as a synthetic analogue of the pharmacopoeia drug Epithalamin
Cell mechanism research
2003 to 2025
Telomere findings remain cell evidence rather than proof of human anti-aging benefit.
- 2003Telomerase lengthThe originating laboratory reported telomerase activity and longer telomeres after Epithalon exposure in cultured human cells. This was a cell in-vitro validated study.
- 27 April 2004US patent 6,727,227 B1Epithalon, a tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application, credited to Khavinson. The patent was published originally in Russia.
Human evidence boundary
2003 to 2003
The mortality report is observational and does not isolate synthetic Epithalon.
- 2003A peptide-bioregulator cohort reports lower mortalityThe paper combines pineal and thymus peptide preparations and does not provide a randomized test of synthetic Epithalon, this study is in mice.
The numbers behind the grade
- Type
- Tetrapeptide (AEDG)
- Mechanism
- Telomerase activation
- Research
- 40+ years
- Independent RCTs
- None
- FDA review
- July 2026
- Approved
- No
The people taking it
The audience is pursuing longevity: biohackers drawn by the telomere story, older adults hoping to sleep better, and clinic patients on Khavinson-style protocols. These are the visible communities a gray market shows.
The flagship longevity peptide and the most famous "telomerase activator" in the consumer space, a staple of anti-aging protocols and by far the most-studied of the Khavinson bioregulators.
Epithalon’s users are longevity-focused: biohackers and anti-aging enthusiasts drawn by the telomere story, older adults hoping to slow aging or improve sleep, and clinic patients on Khavinson-style protocols. The audience skews toward people actively pursuing life extension rather than treating a specific illness, and as with all gray-market compounds there is no reliable demographic data beyond the visible longevity communities.
Used gray-market and as a bioregulator supplement for longevity, telomere maintenance and sleep or circadian support, almost entirely outside approved medicine. Its standing rests on the Russian tradition plus a 2025 independent in-vitro confirmation of its mechanism.
Set against the alternatives
Among the Khavinson bioregulators, Epithalon is the flagship: the most studied, the one with an independently confirmed in-vitro mechanism, and the one facing formal FDA review, which sets it apart from organ-specific peptides like Thymalin or Cortexin whose evidence is thinner and entirely in-tradition. Among telomere-focused longevity products more broadly, it sits alongside supplements like TA-65 (a cycloastragenol product) that also claim telomerase activation without proven human lifespan benefit. And against the broader field of aging interventions, the honest baseline is that nothing has been proven to extend human lifespan; Epithalon, for all its research depth, is not an exception to that.
What we do not know
- Whether an independent randomized human trial can show a meaningful clinical benefit.
- Whether telomere-maintenance effects seen in cells occur after dosing people.
- Whether systemic telomerase or alternative telomere activation would raise cancer risk.
- Whether reported sleep and melatonin effects can be reproduced independently.
- Whether FDA and HHS complete rulemaking after the July 2026 advisory recommendation; the committee vote itself was not approval.
What could change
The July 2026 FDA reviewIts first formal Western regulatory evaluation, a real inflection point.Independent human trialsThe missing piece that would test whether the longevity claims hold up.The telomerase-cancer questionContinued scrutiny of whether activating telomerase is safe over time.Sleep and circadian useThe melatonin-restoring effect may prove its most defensible application.
Legal status
Epithalon is not FDA-approved for any indication. In April 2026 it was removed from the restricted compounding list, reopening a compounding pathway, and an FDA advisory committee is scheduled to evaluate it in July 2026 (neither step is approval). It is sold internationally as a Cytogen-line bioregulator supplement and as a research-use-only peptide, with legal status varying by country. There is no approved medical use, so any use sits in the gray or supplement space.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Available as a Cytogen-line bioregulator supplement, as research-use-only peptide vials from online vendors, and through longevity clinics. None is an FDA-approved medicine, so there is no regulated prescription route; anyone using it should insist on a third-party certificate of analysis and be clear-eyed that the human longevity evidence is weak and the cancer question unresolved.
Both the branded bioregulator supplement and gray-market research vials are relatively inexpensive, which supports its popularity in longevity protocols. Clinic programs cost more once consultations and markups are added. The low price of a research vial again comes with no guarantee of identity, dose or purity.
Material comes from the Russian Cytogen and Cytomax lines and, more commonly, from Chinese research-peptide synthesis. Neither guarantees the identity or potency claimed, so an independent certificate of analysis is the only real check, and it does not substitute for pharmaceutical-grade controls.
Russia (Cytogen / Cytomax)Produced as a branded bioregulator supplement within the Khavinson product lines and exported internationally.China and research vendorsThe dominant gray-market source of research-use-only Epithalon vials sold online worldwide.Longevity clinicsA clinic channel packages it into anti-aging and telomere-focused programs.No approved chainWith no approved product, there is no regulated pharmaceutical supply.
At a glance
- Amino acid sequence
- Ala-Glu-Asp-Gly (AEDG)
- Amino acids
- 4
- Mol. weight
- ~390 Da
- Parent
- Epithalamin (pineal extract)
- Discoverer
- Khavinson (1946-2024)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Epithalon.
Nothing outstanding on this one.
Sources
Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), a synthetic analog of the pineal extract epithalamin developed by Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
In cultured human fetal fibroblast cells, epithalon induced telomerase activity and telomere elongation, allowing the cells to surpass the Hayflick limit, possibly through reactivation of the telomerase gene in somatic cells. The authors suggest this effect points to a possible way of extending the life span of a cell population, though they note this interpretation extends beyond the cell culture findings to a speculative level regarding whole organisms.
Khavinson VKh et al., Bulletin of Experimental Biology and Medicine 2003;135(6):590-592 (Springer)
The pivotal telomerase-activation paper is indexed on PubMed, attributed to the Khavinson group, confirming it is cell-culture work rather than a human efficacy trial.
The longevity signal comes from a Khavinson-group prospective cohort of 266 people over 60 followed 6 to 8 years, reporting a 1.6 to 1.8 fold mortality reduction, which is observational rather than a randomized controlled trial.
The efficacy base is Russian-dominant and has never been fully replicated in large independent Western trials, and epithalon has not been tested in human RCTs.
A 2025 paper from Al-Dulaimi, Thomas, Matta and Roberts, working out of Brunel University London's Centre for Genome Engineering and Maintenance and the Royal Brompton Hospital Respiratory Clinical Research Facility, reports epitalon increases telomere length in human breast cancer cell lines (21NT, BT474) and in normal epithelial and fibroblast cells via telomerase upregulation or ALT activity. The paper states its methods: cells were treated with epitalon and then DNA, RNA and protein were extracted for analysis. On sponsorship, the paper's own funding statement names no external sponsor, citing self-funding PhD students and departmental funding, and it discloses that the epitalon used was supplied as a free research-use-only gift from Peptides of London. This extends the in vitro picture but adds no human efficacy evidence.
Epitalon increases telomere length in human cell lines, PMC (2025)
Epithalon is not FDA-approved and is not approved by the EMA or any major Western regulator; it is sold by research-chemical vendors labeled for laboratory research only.
In July 2026 the FDA Pharmacy Compounding Advisory Committee reviewed epitalon (free base and acetate) among seven peptides nominated for the 503A bulk drug substances list, and FDA briefing documents proposed not adding them; these are advisory proposals, not final determinations.
FDA PCAC July 2026 peptide review coverage (Peptide Dossier / HealingMaps)
Epitalon is not named on the WADA Prohibited List but, as a non-approved pharmacological substance, is captured by the S0 Non-Approved Substances category, which prohibits any substance not approved by a governmental health authority for human therapeutic use.
Epitalon has no FDA approval for any indication and is not a lawful dietary supplement ingredient.
Epitalon is not listed by name on the prohibited list, though unapproved peptides carry catch all risk for tested athletes.
Findings on Epitalon and Epithalamin's effects on rodent lifespan and tumor incidence come predominantly from one Russian research group and lack independent replication. A 2010 Biogerontology review by Anisimov and Khavinson summarizing their own long-term work reports that long-term treatment with some peptide preparations raised mean lifespan by 20 to 40%, slowed age-related changes in markers of aging, and suppressed tumors—both spontaneous and those caused by chemicals or radiation—though the abstract does not specify which peptides or which animals each of these findings comes from.
Anisimov & Khavinson, Peptide bioregulation of aging, Biogerontology review (PubMed)
In a 2004 laboratory study, human fetal lung fibroblasts that had stopped dividing at passage 34 regained telomere length when Epithalon was added and made approximately 10 further divisions, reaching passage 44. The authors interpreted this result as the peptide enabling cells to overcome the Hayflick limit, the natural cap on cell division. These findings come from cells grown in a dish, not from animal or human studies, and the abstract does not provide the number of cultures tested, statistical tests performed, or amount of peptide used.
A Russian and Ukrainian group followed 266 elderly people for six to eight years after two to three years of thymic and pineal peptide preparations (Epithalamin and Thymalin, which are tissue extracts rather than synthetic Epitalon) and reports improved cardiovascular, endocrine, immune and nervous system measures with acute respiratory disease falling 2.0 to 2.4 fold. The authors conclude that these tissue extracts are highly effective at protecting against aging, though the abstract does not describe how people were assigned to treatment or comparison groups.
In female SHR mice dosed monthly from three months old until natural death, Epitalon left food intake, body weight and mean life span unchanged, but extended the life span of the last 10% of survivors by 13.3% and maximum life span by 12.3%, cut bone marrow chromosome aberrations by 17.1%, left total tumour incidence unchanged and reduced leukaemia sixfold. It also slowed the age-related switching-off of the estrous cycle. The authors interpret these results as suggesting Epitalon acts as a geroprotector and that its long-term use was safe in mice.
In HER-2/neu transgenic mice, Epitalon reduced the cumulative number and maximum size of mammary tumors, the size of lung metastases, and the amount of HER-2/neu messenger RNA in tumors compared with controls, while more Epitalon-treated mice developed a single tumor rather than multiple tumors. The comparison peptide Vilon raised mammary cancer incidence in the same experiment, and Epitalon reduced metastasis size but not metastasis number.
A Russian-language report states that pineal gland peptides called Epithalamin and Epitalon restored night melatonin release and normalized its daily rhythm in old monkeys and elderly people with reduced pineal function, with no reported side effects, though the available English abstract does not specify how many participants were involved, how side effects were assessed, or the duration of follow-up.
In old rhesus monkeys aged 20 to 27 years compared with young monkeys aged 6 to 8, epitalon lowered basal glucose and insulin and raised basal night melatonin toward the levels measured in young animals. Before treatment, the old animals had higher basal blood glucose and insulin and lower night melatonin, and after a dose of glucose they showed a larger, slower-clearing rise in blood glucose with a smaller insulin peak at 5 minutes.
In senescence-accelerated and wild-type mice treated from two months old, Epithalon lowered bone marrow chromosome aberrations by 17.9% to 30.1% against age-matched controls, whereas melatonin in drinking water produced no such effect in the same experiment. At 12 months old, senescence-accelerated SAMP-1 female mice had 1.8 times more chromosome aberrations in bone marrow cells than wild-type SAMR-1 females and 2.2 times more than SHR females, representing the age-related damage the treatment was measured against.
A 134-page single-author supplement monograph collects the group’s work on tissue peptide preparations and reports that Epithalamin raises rat melatonin production, produces anticarcinogenic effects in several models and increases lifespan in rats, mice and fruit flies.
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144.
In rats given a colon carcinogen, Epitalon administered throughout the experiment slowed tumor cell division and increased apoptosis in a way the authors report as statistically significant, with the strongest effect seen with continuous treatment. Epitalon also lessened the carcinogen-induced shrinkage of supporting tissue and reduced lymphoid infiltration, while increasing lymphoid infiltration in both tumors and nearby colon lining, again most when given continuously.
In 1994, V.N. Anisimov, V.Kh. Khavinson and V.G. Morozov published a review in the Annals of the New York Academy of Sciences. By its title, the review looks back on twenty years of study of epithalamin, the pineal gland peptide preparation that came before Epithalon, in experimental aging research and cancer research. The record read shows only the title and publication details, not the review's findings, so no findings are reported here. The review concerns the extract, not the synthetic four-amino-acid peptide.
A 1998 study of epithalamin, a pineal gland extract, found that female fruit flies, two strains of mice and rats treated with the extract lived 11 to 31% longer on average, with the increase reported as statistically significant, and maximum lifespan also rose in fruit flies, one mouse strain and rats. Mortality rate fell by 52% in fruit flies and rats and 27% in one mouse strain, while mortality rate doubling time grew longer in these groups. The authors propose that epithalamin's effects on melatonin production and its antioxidant properties in reducing free radical processes explain these lifespan increases, though these are results from insects and rodents given the extract, not the synthetic peptide, and say nothing about people.
Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats.
A 12-year randomized clinical study of epithalamine, a pineal gland peptide preparation, followed elderly people with coronary heart disease whose heart and blood vessels were aging faster than usual. The study reported that 28% fewer people died in the epithalamine group than in the control group, with deaths from cardiovascular disease and cardiovascular failure occurring at about half the rate in the treated group, though the abstract provided no patient numbers, confidence intervals, or P values for these figures. Long-term epithalamine treatment also reportedly lowered patients' functional age and the degree of aging in their heart and blood vessels while raising exercise tolerance, though how these measures were assessed and the magnitude of change were not described. These results are for the natural extract rather than synthetic Epithalon, come from a team that includes the extract's developer, and lack detail on randomization procedures and blinding.
A 2011 randomized comparative study in elderly coronary patients with accelerated aging of the heart and blood vessels found that 39 patients receiving regular courses of epithalamin (an extract from the pineal gland) alongside basic therapy over three years had significantly lower mortality than 40 control patients receiving basic therapy alone, though the abstract provides no death counts, P values, or specific time points for comparison. The same study reports that long-term epithalamin treatment slowed aging of the heart and blood vessels, prevented age-related loss of physical endurance, restored normal daily rhythm of melatonin production, and normalized carbohydrate and lipid metabolism in treated patients, though the abstract does not specify the measures used or the magnitude of these changes.
In a 2003 lab study by Khavinson, Lezhava and colleagues, researchers added Epitalon to cultured white blood cells (lymphocytes) from people aged 76 to 80. In these cells, Epitalon switched on ribosomal genes, loosened tightly packed DNA regions near the centers of chromosomes (pericentromeric heterochromatin), and released genes that had been silenced as DNA packed more tightly with age. The authors conclude that Epitalon can activate chromatin, the packaged form of DNA, in cells of older people. These are measurements in cells in a dish, and the people who gave the cells were not treated. The abstract does not say how many people gave cells or how large the changes were.
In a rat study, intranasal Epitalon produced a slight but statistically significant increase in C-Fos protein in pineal cells only under osmotic stress, not in unstressed animals, and partly reduced the widening of blood vessels and surrounding spaces in the stressed pineal gland, though the number of rats and size of the change were not specified. The authors propose that Epitalon adjusts pineal secretion under stress conditions by activating proto-oncogenes in pineal cells, based on this single animal study with no measurement of sleep or outcomes in people.
Epitalon influences pineal secretion in stress-exposed rats in the daytime.
The accessible text of WO2025037992A1 states that the invention's N-acetylated, C-terminal arginine-amide peptides, including the Epithalon-derived compound, 'exhibit better stability and at the same time... improved biological activities in comparison to their parent compounds as presented in detail in the Examples below'; the general formulation section lists pharmaceutically acceptable inactive ingredients for liquid oral preparations, naming suspending agents such as sorbitol syrup, cellulose derivatives or hydrogenated edible fats, emulsifying agents such as lecithin or acacia, non-aqueous vehicles such as almond oil, oily esters, ethyl alcohol or fractionated vegetable oils, and preservatives such as methyl or propyl hydroxybenzoate or sorbic acid, plus buffers, flavoring agents, coloring agents and sweeteners. The retrieved text does not state a numeric shelf life or storage duration, does not describe defined storage temperature conditions, and does not name a manufacturer or sponsor; the page shows a 'Current Assignee' field but no assignee name was present in the text that could be retrieved. The specific wording used in the prior version of this finding, that patent examples test Epithalon lyophilizate and aqueous preparations under defined laboratory conditions, was not found in the portions of the document that could be read; what could be confirmed instead was a cell-culture example treating fibroblasts with Epithalon or its acetylated analog, and the general stability and excipient language quoted above.
A 2025 review by researchers at the Medical University of Warsaw and Nicolaus Copernicus University in Poland describes Epitalon (Ala-Glu-Asp-Gly), a four-amino-acid chain first synthesized in the lab to match the composition of epithalamin, a bovine pineal gland extract, and later found in the pineal gland's own peptide mixture. The review covers 25 years of research in cells, living organisms, and computer models, with authors concluding that these studies point to anti-aging and hormone-system effects linked to antioxidant, nerve-protecting, and anti-mutation activity, though the abstract does not specify how many studies involved people. Reported effects include direct effects on melatonin production, changes in interleukin-2 messenger RNA, changes in how mouse thymus cells multiply, and higher activity of enzymes AChE, BuChE, and telomerase, though the review notes it remains uncertain whether these are the only mechanisms of action. The review describes a clinical trial in retinitis pigmentosa at the St. Petersburg Institute of Bioregulation and Gerontology involving 162 patients aged 18 to 72 who received injections of epitalon beside the eyeball for 10 days, with no reported side effects among treated patients, though the review does not describe randomization or blinding. Sources disagree on whether clinical trials on the synthetic peptide itself have been conducted, with the Polish review stating they have occurred over 25 years while the Alzheimer's Drug Discovery Foundation states they have not, and it remains unclear which human studies used the synthetic peptide and which used the extract epithalamin.
In a laboratory study of human stem cells from gum tissue, AEDG (Epitalon) increased production of four markers of early nerve-cell development—Nestin, GAP43, beta Tubulin III, and Doublecortin—with messenger RNA for these markers rising by 1.6 to 1.8 times at a significance threshold of P < 0.01. Computer modelling predicted that AEDG binds preferentially to histones H1/3 and H1/6 at sites that interact with DNA, which the authors propose may be one mechanism by which the peptide increases activity of nerve-development genes, though this binding was predicted by computer rather than measured in cells. These are results in cells grown in a dish, not in people.
The Alzheimer's Drug Discovery Foundation's Cognitive Vitality summary reports that clinical studies on epithalon have not been conducted, while epithalamin, the pineal extract, is approved in Russia for menopause-related symptoms, anovulatory infertility, and hormone-dependent tumors, but not approved for any medical use outside Russia. The clinical trials reviewed used different doses, delivery routes and schedules including nasal delivery and intramuscular injection, though some animal experiments used subcutaneous injection with no human data available for that route. The summary notes that at least half of roughly 110 published articles on epithalamin and epithalon are in Russian and were excluded from its analysis, so the review does not cover the full literature.
Alzheimer's Drug Discovery Foundation, Cognitive Vitality for Researchers: Epithalamin/Epithalon
In a May 12, 2026 evaluation, the FDA proposed that neither epitalon free base nor epitalon acetate be added to the 503A Bulks List for pharmacy compounding, treating synthetic epitalon as distinct from epithalamin extracted from pineal glands. The evaluation identified a 2021 randomized, placebo-controlled study of epitalon in women that measured a breakdown product of melatonin in urine but did not measure sleep, did not report blinding status, and showed no benefit for insomnia. The FDA also noted that naming practices for epitalon-related substances create uncertainty about which form—free base or acetate—a given reference standard refers to.
FDA Evaluation of Epitalon-Related Bulk Drug Substances (Epitalon (Free Base) and Epitalon Acetate)
The FDA's Pharmacy Compounding Advisory Committee scheduled epitalon free base and epitalon acetate for discussion on July 23–24, 2026 (FDA-2025-N-6895), as candidates for the 503A Bulks List alongside emideltide and Semax. The FDA reviewed epitalon in relation to insomnia, though people have suggested other uses.
FDA, July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
PubChem's epitalon record lists two CAS registry numbers: 307297-39-8 and 64082-79-7. FDA's 2026 evaluation gives 307297-39-8 as the number for epitalon free base. PubMed attaches 64082-79-7 to epithalamin, the pineal gland extract. The two numbers are recorded here as printed and are not reconciled.
PubChem lists epitalon (compound ID 219042) as the four-amino-acid peptide Ala-Glu-Asp-Gly (AEDG), with the molecular formula C14H22N4O9 and a molecular weight of 390.35 g/mol, though these figures describe the synthetic peptide and not epithalamin, the separate pineal extract.
A 2025 study in human cell lines reported that epitalon lengthened telomeres through telomere maintenance mechanisms, with a correction published in Biogerontology on November 15, 2025 addressing errors in Figures 1, 2, and 3. The study treated two breast cancer cell lines at concentrations of 0.1 to 1 microgram per millilitre for 4 days and two non-cancer cell types at 1 microgram per millilitre for 3 weeks, representing laboratory work in cells with no human data.
FDA's orphan drug database records that epitalon received orphan designation on September 2, 2010 to treat retinitis pigmentosa, sponsored by BioDiem Ltd of Australia. Orphan designation is a status for drugs being developed for rare conditions and is not an approval; the record states that epitalon is not FDA approved for this use. The database later shows the status of this 2010 designation as "Designated/Designation Withdrawn or Revoked," though it does not provide a date for the withdrawal or revocation or specify which occurred.
In a 2002 report, epitalon increased the electrical and functional activity of retinas in Campbell rats bred to develop inherited retinal degeneration, and the authors linked this to retention of retinal structure. The same report stated that epitalon treatment gave a positive clinical effect in 90% of patients with degenerative retinal disease, though the abstract does not specify the number of patients, define what constituted a positive effect, describe follow-up duration, or indicate whether patients were randomly assigned or blinded. PubMed indexed this 2002 paper as a clinical trial and controlled clinical trial, a classification that conflicts with statements that no human clinical trial of synthetic epitalon exists.
Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa
A 2020 Russian paper reports that the AEDG peptide raised the amount of 6-sulfatoxymelatonin, a breakdown product of melatonin, in the urine of middle-aged people by 1.7 times, and in people with reduced melatonin output from the pineal gland, changed body-clock genes in blood cells, with overactive Clock and Csnk1e genes in white blood cells returning toward normal by 1.9 to 2.1 times and the underactive Cry2 gene in lymphocytes becoming twice as active. The authors interpreted these changes as the peptide restoring the pineal gland's melatonin production. The abstract provides no information on the number of participants, how they were assigned, whether there was a comparison group, or any sleep or safety results.
Upregulates telomerase activity to lengthen telomeres and by stimulating pineal melatonin production to help regulate circadian rhythms. Telomerase Activation: Epithalon (a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly) is proposed to stimulate human telomerase reverse transcriptase (hTERT) expression. This enzyme rebuilds and maintains telomeres—the protective caps at the ends of chromosomes—potentially delaying cellular senescence and death.Melatonin and Circadian Regulation: Modeled on the pineal gland extract epithalamin, Epithalon has been observed in preclinical and older animal/primate studies to restore or normalize melatonin secretion, which supports sleep quality and circadian alignment.Antioxidant and Gene Modulation: Research indicates it may decrease reactive oxygen species (ROS), reduce lipid peroxidation, influence protein synthesis, and alter immune-related markers like interleukin-2 mRNA levels.
The studies that matter
Khavinson, Bondarev & Butyugov (human cells)2003
Showed Epithalon induced telomerase activity and lengthened telomeres in human fibroblasts, extending their replicative lifespan by roughly 40%, the foundational mechanism finding, though from a single cell type and the originating lab.
Anisimov & Khavinson (mice)2002-2003
Reported extended lifespan (around 12 to 13%) and reduced spontaneous tumor incidence in mouse models, the core animal longevity evidence.
Long-term human cohort (Korkushko and colleagues)2000s
A multi-year study in elderly subjects claimed reduced mortality and improved markers, but it was non-blinded, non-randomized and from the same tradition.
Al-Dulaimi et al, Biogerontology2025
An independent Western laboratory confirmed that Epitalon increases telomere length in human cell lines via telomerase or an alternative pathway, the first outside validation of the mechanism, though still in vitro, not clinical.
Independent human longevity trialsnone
No independent, randomized, controlled human trial of Epithalon for aging or mortality endpoints has been published.